Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Future of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistance

Description du projet

De meilleures options thérapeutiques pour un lymphome non hodgkinien rare

Le lymphome anaplasique à grandes cellules (ALCL) est un lymphome non hodgkinien rare qui touche toutes les tranches d’âge, avec une incidence plus élevée chez les enfants et les jeunes adultes. Il peut se manifester sous la forme d’une maladie systémique ou localisée avec des symptômes tels que le gonflement des ganglions lymphatiques, de la fièvre, de la fatigue et une perte de poids. Les options thérapeutiques sont notamment la chimiothérapie, la radiothérapie et la greffe de cellules souches. Le projet FANTOM, soutenu par le programme Actions Marie Skłodowska-Curie, entend former des chercheurs dans le domaine de l’ALCL en recourant à des systèmes modèles innovants et des technologies multi-omiques. Il étudiera les rôles du système immunitaire et du stroma tumoral, en développant des biomarqueurs non invasifs et de nouvelles approches thérapeutiques. Ce projet nous permettra de mieux comprendre l’ALCL et d’offrir de meilleures options de traitement aux personnes affectées.

Objectif

The FANTOM Doctoral Network (DN) composed of 7 beneficiaries and 12 associated partners in 5 EU countries, recruiting 10 researchers and will be embedded into an established international research programme: The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA) as well as a clinical network: The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). FANTOM will cosset and nurture the recruited researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives welcomed into these established networks. This will be achieved through a training programme conducted through research and complemented by a balanced programme of transferable skills designed with key input from both academic and industrial collaborators. The training of each fellow will be guided by an individual career development plan and supervised by a PhD committee with clearly allocated academic and industrial supervisors. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into the aforementioned networks. The research programme will address the clinical problems posed by Anaplastic Large Cell Lymphoma (ALCL) typified by aberrant ALK expression. Applying innovative model systems and multi-omics technologies, some performed to a single cell level, the biology of ALCL including the roles of the immune system and tumour stroma will be uncovered. These data will be applied to the development of (non-invasive) biomarkers and novel therapeutic approaches that will culminate in the design of clinical trials to address the issues of chemotherapy toxicity, over-treatment and drug resistance. The research and training activities will incorporate not only academic labs but also key research institutes, biotechnology companies, clinical trial bodies and Pharma to realise our research goals.

Coordinateur

Masarykova univerzita
Contribution nette de l'UE
€ 474 076,80
Adresse
Zerotinovo namesti 9
601 77 Brno
Tchéquie

Voir sur la carte

Région
Česko Jihovýchod Jihomoravský kraj
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée

Participants (7)

Partenaires (14)